@article{TLCR23047,
author = {Giulio Metro and Massimo Di Maio},
title = {Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 3},
year = {2018},
keywords = {},
abstract = {Targeted treatment with a tyrosine kinase inhibitor (TKI) is associated with high response rates and significantly prolonged progression-free survival in the minority of patients (approximately 15–20%) with advanced non-small cell lung cancer (NSCLC) whose tumor harbors an epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) rearrangement or ROS1 rearrangement (1).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/23047}
}